Biovail Faces Grand Jury Probe On Cardizem Launch
Biovail announced on Friday that the U.S. attorney had informed the company that it was the subject of a grand jury inquiry into its activities surrounding the 2003 introduction of Cardizem(R) LA.
“As previously disclosed, the investigation commenced in 2003 as an administrative inquiry,” Biovail said. “The corporation has been...
To view the full article, register now.